Want to see AU:CU6 full AI Analyst Report?
Total Valuation
Clarity Pharmaceuticals Ltd. has a market cap or net worth of AU$716.32M. The enterprise value is AU$619.33M.
Market CapAU$716.32M
Enterprise ValueAU$619.33M
Share Statistics
Clarity Pharmaceuticals Ltd. has 373,081,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding373,081,240
Owned by Insiders0.27%
Owned by Institutions―
Financial Efficiency
Clarity Pharmaceuticals Ltd.’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -58.41%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-58.41%
Return on Capital Employed (ROCE)-0.64
Revenue Per Employee0.00
Profits Per Employee-1.07M
Employee Count100
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clarity Pharmaceuticals Ltd. is ―. Clarity Pharmaceuticals Ltd.’s PEG ratio is -0.16.
PE Ratio―
PS Ratio0.00
PB Ratio4.23
Price to FCF-8.48
Price to Operating Cash Flow-7.53
PEG Ratio-0.16
Income Statement
In the last 12 months, Clarity Pharmaceuticals Ltd. had revenue of 0.00 and earned -107.14M in profits. Earnings per share was -0.29.
Revenue0.00
Gross Profit-283.53K
Operating Income-118.91M
Pretax Income-116.81M
Net Income-107.14M
EBITDA-118.62M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -92.55M and capital expenditures -306.92K, giving a free cash flow of -92.85M billion.
Operating Cash Flow-92.55M
Free Cash Flow-92.85M
Free Cash Flow per Share-0.25
Dividends & Yields
Clarity Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.38
52-Week Price Change-64.31%
50-Day Moving Average2.32
200-Day Moving Average2.77
Relative Strength Index (RSI)36.20
Average Volume (3m)1.89M
Important Dates
Clarity Pharmaceuticals Ltd. upcoming earnings date is Mar 4, 2027, TBA (Confirmed).
Last Earnings DateAug 27, 2026
Next Earnings DateMar 4, 2027
Ex-Dividend Date―
Financial Position
Clarity Pharmaceuticals Ltd. as a current ratio of 16.09, with Debt / Equity ratio of 0.00%
Current Ratio16.09
Quick Ratio16.09
Debt to Market Cap0.00
Net Debt to EBITDA1.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Clarity Pharmaceuticals Ltd. has paid -9.67M in taxes.
Income Tax-9.67M
Effective Tax Rate0.08
Enterprise Valuation
Clarity Pharmaceuticals Ltd. EV to EBITDA ratio is -5.14, with an EV/FCF ratio of -6.56.
EV to Sales0.00
EV to EBITDA-5.14
EV to Free Cash Flow-6.56
EV to Operating Cash Flow-6.58
Balance Sheet
Clarity Pharmaceuticals Ltd. has AU$178.25M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$178.25M billion.
Cash & Marketable SecuritiesAU$178.25M
Total DebtAU$0.00
Net CashAU$178.25M
Net Cash Per ShareAU$0.48
Tangible Book Value Per ShareAU$0.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Clarity Pharmaceuticals Ltd. is AU$6.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$6.79
Price Target Upside171.73% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-44.83%